Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Axogen, Inc.
Report date March 16, 2023 · Filed March 20, 2023
Section 16 reporting ended · disclosed 2023-03-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,698 |
Reported balance
After 2023-03-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-03-16 · Exercise / conversion · Acquired 5,900 · Balance 23,698 F1: This reflects the number of restricted stock units that became vested as of March 16, 2023. F2: Includes 3,000 shares acquired under the Axogen stock purchase plan in 2022. |
| Common StockSEC Table I · non-derivative | Direct | 22,900 |
Reported balance
After 2023-03-16 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-03-16 · Tax withholding · Disposed 798 · Balance 22,900 F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. |
| Common StockSEC Table I · non-derivative | Direct | 25,463 |
Reported balance
After 2023-03-16 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2023-03-16 · Exercise / conversion · Acquired 2,563 · Balance 25,463 F1: This reflects the number of restricted stock units that became vested as of March 16, 2023. |
| Common StockSEC Table I · non-derivative | Direct | 23,627 |
Reported balance
After 2023-03-16 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2023-03-16 · Tax withholding · Disposed 1,836 · Balance 23,627 F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 5,900 |
Reported balance
After 2023-03-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-03-16 · Exercise / conversion · Disposed 5,900 · Balance 5,900 F4: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F5: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023, 25% of the aggregate shares vest on March 16, 2024, and 25% of the aggregate shares vest on March 16, 2025. Vested shares will be delivered to the reporting person upon the vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 2,564 |
Reported balance
After 2023-03-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-03-16 · Exercise / conversion · Disposed 2,563 · Balance 2,564 F4: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F6: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (3 years from the grant date) based upon a vesting schedule whereby 33.33% of the aggregate shares vest on March 16, 2022, 33.33% of the aggregate shares vest on March 16, 2023, and 33.34% of the aggregate shares vest on March 16, 2024. Vested shares will be delivered to the reporting person upon the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This reflects the number of restricted stock units that became vested as of March 16, 2023.
F2: Includes 3,000 shares acquired under the Axogen stock purchase plan in 2022.
F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F4: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
F5: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023, 25% of the aggregate shares vest on March 16, 2024, and 25% of the aggregate shares vest on March 16, 2025. Vested shares will be delivered to the reporting person upon the vesting date.
F6: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (3 years from the grant date) based upon a vesting schedule whereby 33.33% of the aggregate shares vest on March 16, 2022, 33.33% of the aggregate shares vest on March 16, 2023, and 33.34% of the aggregate shares vest on March 16, 2024. Vested shares will be delivered to the reporting person upon the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 16, 2023 Filed Mar 20, 2023 22:50 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 2,563 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000026 · wf-form4_167935260755119.xml · derivative · entry 6 Ottinger Bradley · CIK 0001813381 · General Counsel and CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,564 Underlying: Common Stock · 2,563 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F6 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (3 years from the grant date) based upon a vesting schedule whereby 33.33% of the aggregate shares vest on March 16, 2022, 33.33% of the aggregate shares vest on March 16, 2023, and 33.34% of the aggregate shares vest on March 16, 2024. Vested shares will be delivered to the reporting person upon the vesting date. F6 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (3 years from the grant date) based upon a vesting schedule whereby 33.33% of the aggregate shares vest on March 16, 2022, 33.33% of the aggregate shares vest on March 16, 2023, and 33.34% of the aggregate shares vest on March 16, 2024. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 22:50 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 5,900 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000026 · wf-form4_167935260755119.xml · derivative · entry 5 Ottinger Bradley · CIK 0001813381 · General Counsel and CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,900 Underlying: Common Stock · 5,900 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F5 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023, 25% of the aggregate shares vest on March 16, 2024, and 25% of the aggregate shares vest on March 16, 2025. Vested shares will be delivered to the reporting person upon the vesting date. F5 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023, 25% of the aggregate shares vest on March 16, 2024, and 25% of the aggregate shares vest on March 16, 2025. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 22:50 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 1,836 | $8.27 | $15,183.72 |
DisclosureSEC source: 0000805928-23-000026 · wf-form4_167935260755119.xml · nonDerivative · entry 4 Ottinger Bradley · CIK 0001813381 · General Counsel and CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,627 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 22:50 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 2,563 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000026 · wf-form4_167935260755119.xml · nonDerivative · entry 3 Ottinger Bradley · CIK 0001813381 · General Counsel and CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,463 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2023. Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 22:50 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 798 | $8.27 | $6,599.46 |
DisclosureSEC source: 0000805928-23-000026 · wf-form4_167935260755119.xml · nonDerivative · entry 2 Ottinger Bradley · CIK 0001813381 · General Counsel and CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,900 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 22:50 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 5,900 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000026 · wf-form4_167935260755119.xml · nonDerivative · entry 1 Ottinger Bradley · CIK 0001813381 · General Counsel and CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,698 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2023. F2 · balance_after: Includes 3,000 shares acquired under the Axogen stock purchase plan in 2022. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:11 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 15,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000066 · wf-form4_165428708809863.xml · derivative · entry 3 Ottinger Bradley · CIK 0001813381 · General Counsel and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,500 Underlying: Common Stock · 15,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on June 1, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on June 1, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F4 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on June 1, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on June 1, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:11 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 3,775 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000066 · wf-form4_165428708809863.xml · nonDerivative · entry 2 Ottinger Bradley · CIK 0001813381 · General Counsel and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,798 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:11 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 15,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000066 · wf-form4_165428708809863.xml · nonDerivative · entry 1 Ottinger Bradley · CIK 0001813381 · General Counsel and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,573 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that vested on June 1, 2022. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:09 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 41,948 | $0.00 Strike: $8.20 | $0.00 |
DisclosureSEC source: 0000805928-22-000032 · wf-form4_164763412024331.xml · derivative · entry 5 Ottinger Bradley · CIK 0001813381 · General Counsel and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,948 Underlying: Common Stock · 41,948 shares Expires 2032-03-16 F7 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2026 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2024 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:09 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 44,973 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000032 · wf-form4_164763412024331.xml · derivative · entry 4 Ottinger Bradley · CIK 0001813381 · General Counsel and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,973 Underlying: Common Stock · 44,973 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F6 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F6 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:09 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 2,563 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000032 · wf-form4_164763412024331.xml · derivative · entry 3 Ottinger Bradley · CIK 0001813381 · General Counsel and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,127 Underlying: Common Stock · 2,563 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F5 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (3 years from the grant date) based upon a vesting schedule whereby 33.33% of the aggregate shares vest on March 16, 2022, 33.33% of the aggregate shares vest on March 16, 2023, and 33.34% of the aggregate shares vest on March 16, 2024. Vested shares will be delivered to the reporting person upon the vesting date. F5 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (3 years from the grant date) based upon a vesting schedule whereby 33.33% of the aggregate shares vest on March 16, 2022, 33.33% of the aggregate shares vest on March 16, 2023, and 33.34% of the aggregate shares vest on March 16, 2024. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:09 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 648 | $7.97 | $5,164.56 |
DisclosureSEC source: 0000805928-22-000032 · wf-form4_164763412024331.xml · nonDerivative · entry 2 Ottinger Bradley · CIK 0001813381 · General Counsel and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,073 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:09 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 2,563 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-22-000032 · wf-form4_164763412024331.xml · nonDerivative · entry 1 Ottinger Bradley · CIK 0001813381 · General Counsel and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,721 F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2022. F2 · balance_after: Includes 1,158 shares acquired under the Axogen stock purchase plan in 2021. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 21:54 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 7,690 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000060 · wf-form4_161610444382775.xml · derivative · entry 3 Ottinger Bradley · CIK 0001813381 · General Counsel and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,490 Underlying: Common Stock · 7,690 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (3 years from the grant date) based upon a vesting schedule whereby 33.33% of the aggregate shares vest on March 16, 2022, 33.33% of the aggregate shares vest on March 16, 2023, and 33.34% of the aggregate shares vest on March 16, 2024. Vested shares will be delivered to the reporting person upon the vesting date. F4 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (3 years from the grant date) based upon a vesting schedule whereby 33.33% of the aggregate shares vest on March 16, 2022, 33.33% of the aggregate shares vest on March 16, 2023, and 33.34% of the aggregate shares vest on March 16, 2024. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 21:54 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 11,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-21-000060 · wf-form4_161610444382775.xml · derivative · entry 2 Ottinger Bradley · CIK 0001813381 · General Counsel and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,800 Underlying: Common Stock · 11,800 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 21:54 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 23,500 | $0.00 Strike: $20.91 | $0.00 |
DisclosureSEC source: 0000805928-21-000060 · wf-form4_161610444382775.xml · derivative · entry 1 Ottinger Bradley · CIK 0001813381 · General Counsel and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2031-03-16 F1 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2025 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:25 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 31,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-006875 · edgar.xml · derivative · entry 2 Ottinger Bradley · CIK 0001813381 · General Counsel and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,000 Underlying: Common Stock · 31,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on June 1, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on June 1, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F3 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on June 1, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on June 1, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:25 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 67,000 | $0.00 Strike: $9.72 | $0.00 |
DisclosureSEC source: 0001179110-20-006875 · edgar.xml · derivative · entry 1 Ottinger Bradley · CIK 0001813381 · General Counsel and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Stock · 67,000 shares Expires 2030-06-01 F1 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on June 1, 2024 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on June 1, 2022 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.